Rising development costs make biosimilar market entry a difficult proposition

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry, according to market experts.

They claim the current industry average cost of bringing a biosimilar to market is around $100-200 million. This is in addition to a development period ranging from eight to ten ...